Ibn Sina Medical, one of the subsidiaries of the Business Company. Which is one of the leading companies in the supply of medicines, hospitals and health care products in Qatar, and “Novo Nordisk”, the leading Danish International Company in the field of health care, known for its experience in treating chronic diseases such as diabetes and obesity, about the latter of Wigofovi® (Simajlotide 2.4 mg) in Qatar. The effectiveness of the new medicine was attended by His Excellency Mr. Anders Piurne Hansen, Ambassador of the Kingdom of Denmark to the State of Qatar and the United Arab Emirates, Mr. Rashid bin Ali Al Mansouri, CEO of Business Company, Mr. Manfandra Singh, General Manager of “Novo Nordick Qatar”, and Mrs. Nayla Mansour, Commercial Director represented by Mr. Essam Faraj Allah, General Manager of Ibn Sina Medical. The Wigofi® (Simaglotide 2.4 mg) is the first GLP-1RA receptor-acting drug (GLP-1RA) is taken once a week, to treat chronic obesity cases in adults and adolescents from the age of 12 years and over, and the drug is now available in Qatar.
Obesity has become more like a dangerous global epidemic, with nearly a billion people around the world suffering from it. Obesity is spread in the Arabian Gulf region at a rapid pace, recording its highest rates globally, and constitutes a severe crisis in Qatar in particular, where the prevalence of obesity (the BMI ≥ 30 kg/m2) is estimated among adults in Qatar 41%, with a higher scattering among women to 46%, and approximately 76%of individuals in Qatar are classified as suffering from weight gain Qatar is among the top 10 countries in obesity rates in the world. The high rates of obesity and weight gain in Qatar are associated with high levels of chronic related diseases, such as pre -diabetes, diabetes, and cardiovascular diseases.
The active substance of Wigofi (Simaglotide 2.4 mg) reduces the feeling of hunger and increases the feeling of fullness. Wigofi is prescribed as a complementary treatment for reducing the calories consumed and increasing physical activity to control weight, including weight loss and maintaining it in adults with obesity (body mass index ≥ 30 kg/m²) or who suffer from weight gain (body mass index ≥ 27 kg/m²) with at least one pathological condition associated with excess weight.
According to clinical research, Wigofi, in addition to the diet and exercise, achieves a 17% loss rate that lasts for two years, as the weight of a third of patients decreased by at least 20%. Simaglotide 2.4 mg showed a remarkable improvement in other metabolic heart risk factors, such as: waist circumference, blood pressure, fat level, blood sugar indicators, and interactive S. protein.
On this occasion, during the announcement of the announcement, Mr. Rashid bin Ali Al -Mansoori, CEO of a business company, welcomed all the attendees, and highlighted this important step in addressing obesity as one of the challenges facing public health, stressing a commitment of business to continue supporting innovation and infrastructure in the health care sector in the country, through its subsidiary companies, such as Ibn Sina Medical, in line with the National Health Strategy and Qatar National Vision 2030, he also emphasized a commitment to work to support access to the latest health care solutions that would positively affect the lives of individuals and the health of society.
“We are proud of” Novo Nordesque “by bringing more than 100 years of global leadership in treating chronic diseases and 25 years of specialized research in obesity to the State of Qatar. The widow of Wigofi is an important step in treating obesity as a chronic and dangerous disease. While Qatar continues to face high rates of obesity, diabetes and cardiovascular disease, our cooperation with Ibn Sina Medical is extremely important. We are committed together to enhance the health care system and improve therapeutic results through innovative solutions based on scientific foundations. ”
Mr. Essam Faraj Allah, General Manager of Ibn Sina Medical Company, added: “We are committed to Ibn Sina Medical Medical to ensure the reach of the Qatari community to solutions to health care of a global style. This partnership with Novo Nordsek is an important achievement in our march to address the increasing spread of obesity and associated health complications in Qatar. We have a long -term relationship with Novo Nordisk, and we are building together a unified vision on giving priority to the patient’s medical care. The launch of the Wigofi medicine reflects our continuous pursuit of innovative treatments, and enhances our role as a reliable health care partner, in line with the national health strategy in the state. ”
Professor Osama Al -Alami, head of the medical department at Novo Nordisk Qatar, confirmed: “Obesity is the main cause of many complications, and it is the main factor behind the spread of diabetes in Qatar, where it represents 57.5% of diabetes. Diabetes of the second type and cardiovascular disease is one of the biggest contemporary health challenges in the world, and there is an urgent need to prevent any future increase in new obesity situations and its potential complications.